NCT00047736已完成3 期
A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age >=18 years
- •Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC)
- •A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)
- •Measurable or non-measurable disease
- •ECOG performance status of 0 or 1
- •Life expectancy of >=3 months
- •>= 3 weeks since any prior surgery or radiotherapy (>=2 weeks for patients who receive <=30 Gy of radiotherapy involving <25% of the marrow reserve)
- •Use of an effective means of contraception (women of childbearing potential)
- •Able to comply with study and follow-up procedures
排除标准
- •Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology
- •Malignancies within 3 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
- •Symptomatic or untreated brain metastases
- •Prior systemic chemotherapy for NSCLC
- •Prior exposure to agents directed at the HER axis (e.g., ZD1839 [Iressa], C225 [Cetuximab], Trastuzumab [Herceptin])
- •Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible)
- •History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications
- •Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption
- •Pregnancy or lactation
- •Any of the following abnormal baseline hematologic values:
- •Granulocytes count <=1500/uL
- •Platelet count <100,000/uL
- •Any of the following abnormal baseline liver function tests:
- •Serum bilirubin >1.5× upper limit of normal (ULN)
- •Serum ALT and AST >=2.5× ULN (>5× ULN if due to liver metastases)
- •Alkaline phosphatase >=2.5× ULN
- •Other baseline laboratory values:
- •Serum creatinine >1.5× ULN or creatinine clearance <60 mL/min
- •Uncontrolled hypercalcemia (>11.5 mg/dL)
研究者
研究点 (2)
Loading locations...
相似试验
Temporarily Not Available
不适用
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant ChemotherapyNon-small Cell Lung CancerNCT01297101Shanghai Chest Hospital
已完成
3 期
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR MutationsNon-Small Cell Lung CancerNCT01342965Hoffmann-La Roche217
已完成
3 期
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFRNon-Small Cell Lung CancerNCT00446225Spanish Lung Cancer Group174
已完成
3 期
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT00556712Hoffmann-La Roche889
已完成
3 期
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT00883779Hoffmann-La Roche451